You are here

AstraZeneca slumps on report CEO is heading to Teva

Friday, July 14, 2017 - 05:50

Moving to a generic drugmaker, albeit the world's largest, would be a big change in direction for French-born Mr Soriot, 58.


SHARES in AstraZeneca fell more than 5 per cent on Thursday after the company declined to deny a media report that chief executive Pascal Soriot was about to defect to Israel-based Teva Pharmaceutical Industries.

Mr Soriot, who has led the Anglo- Swedish company since 2012,

Market voices on:

Pair your daily business read with the perfect cup of espresso.

Subscribe to The Business Times today to receive your very own Nespresso Inissia coffee machine worth $188.

Find out more at

Powered by GET.comGetCom